

JAN 28 2002

SUMMARY OF SAFETY AND EFFECTIVENESS**DePuy Orthopaedics, Inc.****NAME OF FIRM:**

DePuy Orthopaedics, Inc.
P.O. Box 988
700 Orthopaedic Drive
Warsaw, IN 46581-0988

PO Box 988
700 Orthopaedic Drive
Warsaw, Indiana 46581-0988
USA
Tel: +1 (219) 267 8143
Fax: +1 (219) 267 7196

510(k) CONTACT:

Janet G. Johnson
Group Leader, Regulatory Affairs

TRADE NAME:

DePuy Femoral Heads

COMMON NAME:

Ceramic Femoral Ball Prosthesis

CLASSIFICATION:

888.3353 Hip joint metal/ceramic/polymer, semi-constrained cemented or nonporous uncemented prosthesis

DEVICE PRODUCT CODE:

87 LZO

**SUBSTANTIALLY EQUIVALENT
DEVICES:**

Ceramic Articul/eze Femoral Balls, S-ROM
Ceramic Femoral Heads

DEVICE DESCRIPTION AND INTENDED USE:

The DePuy Ceramic Femoral Heads are available in a diameter of 28mm, with various offset options. The internal bore which is designed to interlock with the external taper on DePuy femoral stems is available in two variations. The Ceramic Heads are intended to attach to femoral stems, thereby providing the femoral articular surface of a total hip replacement. The DePuy Ceramic Femoral Heads are made from an alumina composite material.

BASIS OF SUBSTANTIAL EQUIVALENCE:

The DePuy Ceramic Femoral Heads are identical in design and indications to the ceramic femoral heads that were cleared previously. Testing has shown that the minor adjustments do not affect the performance of the device.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Janet G. Johnson
Group Leader, Regulatory Affairs
DePuy Orthopaedics, Inc.
P.O. Box 988
700 Orthopaedic Drive
Warsaw, Indiana 46581-0988

JAN 28 2002

Re: K011533

Trade/Device Name: DePuy Femoral Heads

Regulation Number: 21 CFR 888.3353

Regulation Name: Hip joint metal/ceramic/polymer, semi-constrained cemented or nonporous uncemented prosthesis

Regulatory Class: II

Product Code: LZO

Dated: November 9, 2001

Received: November 13, 2001

Dear Ms. Johnson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten", with a stylized initial "C" and a long, sweeping horizontal line extending to the right.

Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known) K011533

Device Name DePuy Femoral Heads

Indications for Use:

Total hip arthroplasty is intended to provide increased patient mobility and reduce pain by replacing the damaged hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components. Total hip replacement is indicated in the following conditions:

1. A severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, or congenital hip dysplasia.
2. Avascular necrosis of the femoral head.
3. Acute traumatic fracture of the femoral head or neck.
4. Failed previous hip surgery including joint reconstruction, internal fixation, arthrodesis, hemiarthroplasty, surface replacement arthroplasty, or total hip replacement.
5. Certain cases of ankylosis.

Concurrence of CDRH, Office of Device Evaluation

for Mark A. Miller
(Division Sign-Off)
Division of General, Restorative
and Neurological Devices

510(k) Number K011533

Prescription Use X
(Per 21 CFR 801.109)

OR

Over-The Counter Use

000004